BACKGROUND: Opioid-dependent HIV-infected patients are less likely to receive HIV quality of care indicators (QIs) compared with nondependent patients. Buprenorphine/naloxone maintenance therapy (bup/nx) could affect the quality of HIV care for opioid-dependent patients. METHODS: We abstracted 16 QIs from medical records at nine HIV clinics 12 months before and after initiation of bup/nx versus other treatment for opioid dependence. Summary quality scores (number of QIs received/number eligible × 100) were calculated. We compared change in QIs and summary quality scores in patients receiving bup/nx versus other participants. RESULTS: One hundred ninety-four of 268 participants (72%) received bup/nx and 74 (28%) received other treatment. Mean summary quality scores increased over 12 months for participants receiving bup/nx (45.6% to 51.6%, P < 0.001) but not other treatment (48.6% to 47.8%, P = 0.788). Bup/nx participants experienced improvements in six of 16 HIV QIs versus three of 16 QIs in other participants. Improvements were mostly in preventive and monitoring care domains. In multivariable analysis, bup/nx was associated with improved summary quality score (β 8.55; 95% confidence interval, 2.06-15.0). CONCLUSIONS: In this observational cohort study, HIV-infected patients with opioid dependence received approximately half of HIV QIs at baseline. Buprenorphine treatment was associated with improvement in HIV QIs at 12 months. Integration of bup/nx into HIV clinics may increase receipt of high-quality HIV care. Further research is required to assess the effect of improved quality of HIV care on clinical outcomes.
BACKGROUND: Opioid-dependent HIV-infectedpatients are less likely to receive HIV quality of care indicators (QIs) compared with nondependent patients. Buprenorphine/naloxone maintenance therapy (bup/nx) could affect the quality of HIV care for opioid-dependent patients. METHODS: We abstracted 16 QIs from medical records at nine HIV clinics 12 months before and after initiation of bup/nx versus other treatment for opioid dependence. Summary quality scores (number of QIs received/number eligible × 100) were calculated. We compared change in QIs and summary quality scores in patients receiving bup/nx versus other participants. RESULTS: One hundred ninety-four of 268 participants (72%) received bup/nx and 74 (28%) received other treatment. Mean summary quality scores increased over 12 months for participants receiving bup/nx (45.6% to 51.6%, P < 0.001) but not other treatment (48.6% to 47.8%, P = 0.788). Bup/nxparticipants experienced improvements in six of 16 HIV QIs versus three of 16 QIs in other participants. Improvements were mostly in preventive and monitoring care domains. In multivariable analysis, bup/nx was associated with improved summary quality score (β 8.55; 95% confidence interval, 2.06-15.0). CONCLUSIONS: In this observational cohort study, HIV-infectedpatients with opioid dependence received approximately half of HIV QIs at baseline. Buprenorphine treatment was associated with improvement in HIV QIs at 12 months. Integration of bup/nx into HIV clinics may increase receipt of high-quality HIV care. Further research is required to assess the effect of improved quality of HIV care on clinical outcomes.
Authors: A C Justice; W Holmes; A L Gifford; L Rabeneck; R Zackin; G Sinclair; S Weissman; J Neidig; C Marcus; M Chesney; S E Cohn; A W Wu Journal: J Clin Epidemiol Date: 2001-12 Impact factor: 6.437
Authors: R Andersen; S Bozzette; M Shapiro; P St Clair; S Morton; S Crystal; D Goldman; N Wenger; A Gifford; A Leibowitz; S Asch; S Berry; T Nakazono; K Heslin; W Cunningham Journal: Health Serv Res Date: 2000-06 Impact factor: 3.402
Authors: W C Mathews; J A McCutchan; S Asch; B J Turner; A L Gifford; K Kuromiya; J Brown; M F Shapiro; S A Bozzette Journal: Med Care Date: 2000-07 Impact factor: 2.983
Authors: M A Burnam; E G Bing; S C Morton; C Sherbourne; J A Fleishman; A S London; B Vitiello; M Stein; S A Bozzette; M F Shapiro Journal: Arch Gen Psychiatry Date: 2001-08
Authors: Declan T Barry; Brent A Moore; Michael V Pantalon; Marek C Chawarski; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin Journal: J Gen Intern Med Date: 2007-02 Impact factor: 5.128
Authors: Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Daniel F Weisberg; Amy C Justice; David A Fiellin Journal: J Pain Date: 2014-08-23 Impact factor: 5.820
Authors: Chethan Bachireddy; Michael C Soule; Jacob M Izenberg; Sergey Dvoryak; Konstantin Dumchev; Frederick L Altice Journal: Drug Alcohol Depend Date: 2013-09-27 Impact factor: 4.492
Authors: Benjamin J Oldfield; Nicolas Muñoz; Mark P McGovern; Melissa Funaro; Merceditas Villanueva; Jeanette M Tetrault; E Jennifer Edelman Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Philip T Korthuis; Paula J Lum; Pamela Vergara-Rodriguez; Keith Ahamad; Evan Wood; Lynn E Kunkel; Neal L Oden; Robert Lindblad; James L Sorensen; Virgilio Arenas; Doan Ha; Raul N Mandler; Dennis McCarty Journal: Addiction Date: 2017-02-08 Impact factor: 6.526
Authors: P Todd Korthuis; David A Fiellin; Kathleen A McGinnis; Melissa Skanderson; Amy C Justice; Adam J Gordon; Donna Almario Doebler; Steven M Asch; Lynn E Fiellin; Kendall Bryant; Cynthia L Gibert; Stephen Crystal; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Kevin L Kraemer Journal: J Acquir Immune Defic Syndr Date: 2012-10-01 Impact factor: 3.731
Authors: Philip Todd Korthuis; Kathleen A McGinnis; Kevin L Kraemer; Adam J Gordon; Melissa Skanderson; Amy C Justice; Stephen Crystal; Matthew Bidwell Goetz; Cynthia L Gibert; David Rimland; Lynn E Fiellin; Julie R Gaither; Karen Wang; Steven M Asch; Donald Keith McInnes; Michael E Ohl; Kendall Bryant; Janet P Tate; Mona Duggal; David A Fiellin Journal: Clin Infect Dis Date: 2015-09-03 Impact factor: 9.079